Scandion Oncology announced that the company's Board of Directors has appointed Francois Martelet as new Chief Executive Officer (CEO). Francois will take up his new position on January 2, 2023. Trained as a Medical Doctor with a Master's degree in Business, Francois Martelet is an experienced executive and CEO with a career spanning more than 30 years in the global pharmaceutical and biotech industry and more than 20 years of experience as an executive.

He has significant experience within early and late-stage clinical development in oncology (cancer) as well as business and partnership development. Francois Martelet has worked and held leadership positions in large pharmaceutical companies including Roche, Eli Lilly, Novartis and MSD. He has also been the CEO of a number of biotech companies, most recently Vivesto AB, where he completed a full turnaround and led the build-up of an oncology pipeline through organic and external growth.

Acting CEO & CFO Johnny Stilou will continue in this role until January 2, 2023, and afterwards resume his role as CFO of Scandion.